logo

For the Inventor, By the Inventor

Wenbin Lin

Chicago, IL, United States of America

Wenbin Lin

LinkedIn

This inventor holds 18 USPTO granted patents and 5 published patent applications and 4 EPO patents, primarily in Cancer Therapy. Top assignees: The University of Chicago, The University of North Carolina at Chapel Hill, Savannah River Nuclear Solutions, LLC. Active years: 2005-2024.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Wenbin Lin. Retrieved from https://idiyas.com/inventor/wenbin-lin

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 18 

% Patents Active = 88.9

 

Average Co-Inventor Count = 3.4

ph-index = 5

Forward Citations = 116(Granted Patents)


Location History:

  • Chapel Hill, NC (US) (2005 - 2017)
  • Chicago, IL (US) (2017 - 2024)

Company Filing History:

goldMedal14 out of 968 
 
The University of Chicago
 patents
silverMedal7 out of 1,331 
 
The University of North Carolina at Chapel Hill
 patents
bronzeMedal1 out of 170 
 
Savannah River Nuclear Solutions, LLC
 patents
where one patent can have more than one assignee

Years Active: 2005-2024

Loading Chart...
Loading Chart...
Areas of Expertise:
Nanoparticles
Cancer Therapy
Metal-Organic Frameworks
Photodynamic Therapy
Radiotherapy
Immunotherapy
Chiral Ligands
Catalysis
Bone Disorders
X-Ray Induced Therapy
Chemotherapeutics
Organic Transformations
18 patents (USPTO):Explore Patents
1. 12048682 - Combination of micheliolide derivatives or nanoparticles with ionizing radiation and checkpoint inhibitors for cancer therapy (2024-07-30),
2. 12042788 - Strongly Lewis acidic metal-organic frameworks for continuous flow catalysis (2024-07-23),
3. 11872311 - Metal bisphosphonate nanoparticles for anti-cancer therapy and imaging and for treating bone disorders (2024-01-16),
4. 11826426 - Nanoscale metal-organic layers and metal-organic nanoplates for x-ray induced photodynamic therapy, radiotherapy, radiodynamic therapy, chemotherapy, immunotherapy, and any combination thereof (2023-11-28),
5. 11673125 - Metal oxide-supported earth-abundant metal catalysts for highly efficient organic transformations (2023-06-13),
6. 11389422 - Combination of micheliolide derivatives or nanoparticles with ionizing radiation and checkpoint inhibitors for cancer therapy (2022-07-19),
7. 11246877 - Nanoparticles for chemotherapy, targeted therapy, photodynamic therapy, immunotherapy, and any combination thereof (2022-02-15),
8. 10953393 - Stabilization of active metal catalysts at metal-organic framework nodes for highly efficient organic transformations (2021-03-23),
9. 10806694 - Nanoparticles for photodynamic therapy, X-ray induced photodynamic therapy, radiotherapy, radiodynamic therapy, chemotherapy, immunotherapy, and any combination thereof (2020-10-20),
10. 10780045 - Nanoparticles for photodynamic therapy, X-ray induced photodynamic therapy, radiotherapy, chemotherapy, immunotherapy, and any combination thereof (2020-09-22),
11. 10647733 - Metal-organic frameworks containing nitrogen-donor ligands for efficient catalytic organic transformations (2020-05-12),
12. 10596116 - Metal bisphosphonate nanoparticles for anti-cancer therapy and imaging and for treating bone disorders (2020-03-24),
13. 10517822 - Nanoscale carriers for the delivery or co-delivery of chemotherapeutics, nucleic acids and photosensitizers (2019-12-31),
14. 10206871 - Nanoparticles for photodynamic therapy, X-ray induced photodynamic therapy, radiotherapy, chemotherapy, immunotherapy, and any combination thereof (2019-02-19),
15. 10118169 - Chiral ligand-based metal-organic frameworks for broad-scope asymmetric catalysis (2018-11-06),

Title: Innovator Spotlight: Wenbin Lin - Pioneering Cancer Therapies and Catalysis in Chicago

Introduction:

Wenbin Lin, a prolific inventor based in Chicago, IL, has made significant contributions to the fields of cancer therapy and catalysis. With a remarkable 18 patents to his name, Lin is recognized for his groundbreaking research in developing novel treatment approaches for cancer and advancing catalytic reactions through innovative materials.

Latest Patents:

Among his recent patents is the innovative method involving the combination of micheliolide derivatives or nanoparticles with ionizing radiation and checkpoint inhibitors for cancer therapy. This approach demonstrates synergistic anticancer efficacy, targeting resistant cancer stem cells and sensitizing cancer cells to therapy. Lin's work also extends to the development of strongly Lewis acidic metal-organic frameworks for continuous flow catalysis, which have shown promising applications in various organic group transformations.

Career Highlights:

Lin's expertise and dedication have been honed through his tenure at esteemed institutions such as the University of Chicago and the University of North Carolina at Chapel Hill. His research at these institutions has paved the way for new advancements in the fields of oncology and catalysis, garnering recognition for his innovative approaches and impactful contributions.

Collaborations:

Throughout his career, Wenbin Lin has collaborated closely with notable peers in the field, including Chunbai He and Demin Liu. These collaborations have been instrumental in driving forward cutting-edge research initiatives and fostering a collaborative spirit within the scientific community.

Conclusion:

In conclusion, Wenbin Lin stands as a pioneering figure in the realms of cancer therapy and catalysis, with a track record of innovative patents and significant contributions to the scientific community. His relentless pursuit of novel solutions and collaborative approach underscore his commitment to pushing the boundaries of innovation and making a lasting impact in the field.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…